Based on technology at University of Pennsylvania, iEcure has launched to commercialise gene therapies initially for liver disorders and an option to license more assets.

iEcure, a US-based mutation-agnostic in vivo gene-editing company, has been spun out of University of Pennsylvania with $50m in series A funding co-led by Versant Ventures and OrbiMed Advisors. The spinout will focus on cures for devastating conditions with a high unmet need, and its approach relies on an endonuclease-based gene-editing technology delivered via adeno-associated…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.